Health Economics›Osteosarcoma›Relapsed refractory or metastatic subsequent lines

Relapsed refractory or metastatic subsequent lines

Osteosarcoma · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 151 638	28d	~9.3 mo	~16.2 mo	~2	~R 303 276 PFS proxy · indirect	17
Regorafenib monotherapy Variant #01	—	R 132 655	28d	3.6 mo	—	2	R 265 310 PFS proxy	1
IE Variant #01	—	R 22 128	21d	—	—	~12	~R 265 533 indirect	—
Sorafenib monotherapy Variant #04	—	R 16 002	28d	—	—	~2	~R 32 005 PFS proxy · indirect	1
ICE Variant #05	—	R 12 735	—	—	~13.9 mo	~4	~R 50 942 PFS proxy · indirect	—
Cyclophosphamide and Topotecan Variant #03	—	R 11 936	—	—	—	~15	~R 179 033 indirect	—
Docetaxel and Gemcitabine Variant #01	—	R 6 266	21d	~6.2 mo	—	~9	~R 56 391 PFS proxy · indirect	1
Cyclophosphamide and Etoposide Variant #01	—	R 3 464	28d	—	—	~2	~R 6 929 indirect	—
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	~4.0 mo	~7.5 mo	~7	~R 11 705 PFS proxy · indirect	66
Placebo Partial	—	—	—	1.7 mo	—	—	—	1
Samarium-153 with stem cell support Variant #01	—	—	—	—	—	—	—	—

11 of 11 regimens shown